These results suggest that PRMT5 inhibition may be effective at targeting the population of GBM cells that drive disease progression and promote resistance to radiotherapy and chemotherapy3,4, which will be required for long-term disease control. The gene discussed is PRMT5; the disease is glioblastoma.